<p>世界50强制药公司<br/><br/>Total product sales grew to around $430 billion, but<br/>some companies—including Bristol-Myers Squibb<br/>and Lilly—lost patent coverage on their blockbusters,<br/>had shrinking revenues, and slid a couple of points<br/>each in the ranking. And Elan, which still made the<br/>list with $1.1 billion in sales, actually lost $639 million<br/>for the year and dropped from 37 to 46.<br/>Others companies generated substantial growth,<br/>including most Japanese manufacturers, which in the past few years<br/>had struggled against a weak yen and shrinking government reimbursements.<br/>Eisai and Fujisawa both made the list of the fastest growing<br/>companies. Eisai jumped from 29 to 22, largely on the 80 percent<br/>growth of its proton pump inhibitor。。。。。。 </p><p> <br/></p>